BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Transthyretin-Mediated Amyloidosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Transthyretin-Mediate
 d Amyloidosis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06128629-11313@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nexiguran ziclumeran: Phase 3 readout est. (NCT06128629)
DESCRIPTION:Nexiguran ziclumeran\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: MAGNITUDE: A Phase 3 Study of NTLA-2001 in Partic
 ipants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06128629
URL:https://assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06183931-11166@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Cliramitug: Phase 3 readout est. (NCT06183931)
DESCRIPTION:Cliramitug\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: Study of ALXN2220 Versus Placebo in Adults With ATTR-CM\nEs
 timated primary completion: 6 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cliramitug#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06183931
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223203-10761@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Nucresiran: Phase 3 readout est. (NCT07223203)
DESCRIPTION:Nucresiran\, phase 3\, Transthyretin Amyloidosis with Polyneuro
 pathy.\nStudy: TRITON-PN: A Study to Evaluate the Efficacy and Safety of N
 ucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyn
 europathy\nEstimated primary completion: 27 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nucresiran#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07223203
URL:https://assetmemo.bio/drug/nucresiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679946-10756@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:AMVUTTRA (Vutrisiran): Phase 3 readout est. (NCT06679946)
DESCRIPTION:AMVUTTRA (Vutrisiran)\, phase 3\, Transthyretin Amyloidosis wit
 h Cardiomyopathy.\nStudy: A Study to Evaluate Vutrisiran in Patients With 
 Transthyretin Amyloidosis With Cardiomyopathy\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vut
 risiran#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06679946
URL:https://assetmemo.bio/drug/vutrisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608354-11166@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290206
DTEND;VALUE=DATE:20290207
SUMMARY:Cliramitug: Phase 2 readout est. (NCT07608354)
DESCRIPTION:Cliramitug\, phase 2\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: A Study to Evaluate the Efficacy and Safety of Concomitant 
 Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for 
 Adults Participants With ATTR-CM\nEstimated primary completion: 6 February
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cliramitug#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0760835
 4
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05667493-10798@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Wainua (Eplontersen): Phase 3 readout est. (NCT05667493)
DESCRIPTION:Wainua (Eplontersen)\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: An Extension Study to Assess Long-Term Safety of 
 Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (
 ATTR-CM)\nEstimated primary completion: August 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/eplontersen#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05667493
URL:https://assetmemo.bio/drug/eplontersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052903-10761@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Nucresiran: Phase 3 readout est. (NCT07052903)
DESCRIPTION:Nucresiran\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: TRITON-CM: A Study to Evaluate Nucresiran in Patients With 
 Transthyretin Amyloidosis With Cardiomyopathy\nEstimated primary completio
 n: 28 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nucre
 siran#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07052903
URL:https://assetmemo.bio/drug/nucresiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789483-11166@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20300711
DTEND;VALUE=DATE:20300712
SUMMARY:Cliramitug: Phase 3 readout est. (NCT07789483)
DESCRIPTION:Cliramitug\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: An Open-Label Study to Evaluate the Long-Term Safety and Ef
 ficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy\nEs
 timated primary completion: 11 July 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cliramitug#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07789483
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116473-11047@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT07116473)
DESCRIPTION:Attruby (Acoramidis)\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: To Evaluate the Long-term Safety and Tolerability
  of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE
 )\nEstimated primary completion: November 2037. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/acoramidis#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07116473
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
